Complications of levodopa therapy in Parkinson's disease

被引:2
作者
Dubow, Jordan [1 ]
Olanow, C. Warren [2 ]
机构
[1] Avadel Pharmaceut PLC, Chesterfield, MO 63005 USA
[2] Mt Sinai Hlth Syst, Dept Neurol & Neurosci, New York, NY USA
来源
EXPERT OPINION ON ORPHAN DRUGS | 2019年 / 7卷 / 09期
关键词
Parkinson's disease; motor complications; dyskinesia; wearing off; levodopa; EXTENDED-RELEASE CAPSULES; CARBIDOPA INTESTINAL GEL; PLACEBO-CONTROLLED TRIAL; DEEP-BRAIN-STIMULATION; DOUBLE-BLIND; MOTOR FLUCTUATIONS; INDUCED DYSKINESIA; WEARING-OFF; DOPAMINE; ISTRADEFYLLINE;
D O I
10.1080/21678707.2019.1662294
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Levodopa remains the most effective treatment for the motor symptoms of Parkinson's disease (PD). However, with chronic treatment, PD patients develop motor complications, which consist of motor fluctuations and dyskinesia. Many new treatments, both medical and interventional, have been developed for the treatment of motor complications but there continues to be an unmet medical need for further treatments. Areas covered: This manuscript summarizes the phenomenology, pathophysiology, prevalence and current and future treatments of motor complications in PD patients based on a PubMed literature search from 1950s to present. Expert opinion: Motor complications are prevalent in PD and risk factors for developing these complications are well-known and well characterized. There are many effective medical and interventional treatments for both motor fluctuations and dyskinesia in PD patients. Despite these treatments, many patients still suffer from many hours of 'Off' time or dyskinesia that have a profound negative impact on quality of life. There are many exciting treatments under development for motor complications that may provide additional benefit for PD patients.
引用
收藏
页码:391 / 397
页数:7
相关论文
共 51 条
[1]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[2]  
[Anonymous], 1997, Ann Neurol, V42, P747
[3]  
[Anonymous], 2018, VOYAGER THERAPEUTICS
[4]  
[Anonymous], 2018, SUNOVION ANNOUNCES P
[5]  
[Anonymous], 2017, CVT301 PHASE 3 DATA
[6]   Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients [J].
Antonini, Angelo ;
Fung, Victor S. C. ;
Boyd, James T. ;
Slevin, John T. ;
Hall, Coleen ;
Chatamra, Krai ;
Eaton, Susan ;
Benesh, Janet A. .
MOVEMENT DISORDERS, 2016, 31 (04) :530-537
[7]   Impact of the motor complications of Parkinson's disease on the quality of life [J].
Chapuis, S ;
Ouchchane, L ;
Metz, O ;
Gerbaud, L ;
Durif, F .
MOVEMENT DISORDERS, 2005, 20 (02) :224-230
[8]   A randomized trial of deep-brain stimulation for Parkinson's disease [J].
Deuschl, Guenther ;
Schade-Brittinger, Carmen ;
Krack, Paul ;
Volkmann, Jens ;
Schaefer, Helmut ;
Boetzel, Kai ;
Daniels, Christine ;
Deutschlaender, Angela ;
Dillmann, Ulrich ;
Eisner, Wilhelm ;
Gruber, Doreen ;
Hamel, Wolfgang ;
Herzog, Jan ;
Hilker, Ruediger ;
Klebe, Stephan ;
Kloss, Manja ;
Koy, Jan ;
Krause, Martin ;
Kupsch, Andreas ;
Lorenz, Delia ;
Lorenzl, Stefan ;
Mehdorn, H. Maximilian ;
Moringlane, Jean Richard ;
Oertel, Wolfgang ;
Pinsker, Marcus O. ;
Reichmann, Heinz ;
Reuss, Alexander ;
Schneider, Gerd-Helge ;
Schnitzler, Alfons ;
Steude, Ulrich ;
Sturm, Volker ;
Timmermann, Lars ;
Tronnier, Volker ;
Trottenberg, Thomas ;
Wojtecki, Lars ;
Wolf, Elisabeth ;
Poewe, Werner ;
Voges, Juergen .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :896-908
[9]   A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events [J].
Dewey, RB ;
Hutton, JT ;
LeWitt, PA ;
Factor, SA .
ARCHIVES OF NEUROLOGY, 2001, 58 (09) :1385-1392
[10]   Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome [J].
Evans, AH ;
Katzenschlager, R ;
Paviour, D ;
O'Sullivan, JD ;
Appel, S ;
Lawrence, AD ;
Lees, AJ .
MOVEMENT DISORDERS, 2004, 19 (04) :397-405